Business
Bloomberg Turnaround: AstraZeneca
Jul.03 — For Pascal Soriot, less is more. He’s shed development drugs he sees little chance of becoming viable, relentlessly focused on oncology and bio-pharmaceuticals to replenish the company’s drugs pipeline while throwing AstraZeneca’s doors open to encourage collaboration. Soriot takes us through his turnaround plan and the key to pushing through cultural change.
source